KELLY C MEYERS, APN
Nursing at Dickerson Pike, Nashville, TN
License number
Tennessee 15643
Category
Nursing
Type
Acute Care
Address
Address
3441 Dickerson Pike, Nashville, TN 37207
Phone
(615) 769-4401
(615) 769-4730 (Fax)
(615) 269-0652
(615) 769-4730 (Fax)
(615) 269-0652
Personal information
See more information about KELLY C MEYERS at radaris.comName
Address
Phone
4998 Clarksville Hwy LOT 3, Whites Creek, TN 37189
7540 Twin Brooks Blvd, Knoxville, TN 37918
713 Blackstone Ave, Madison, TN 37115
1145 Sara Cv, Cordova, TN 38018
3808 Oak Valley Dr, Knoxville, TN 37918
Professional information
See more information about KELLY C MEYERS at trustoria.com
Kelly C Meyers, Nashville TN - APN
Kelly C Meyers, Nashville TN - APN
Specialties:
Nursing (Nurse Practitioner), Acute Care Nursing (Nurse Practitioner)
Address:
3441 Dickerson Pike SUITE 201, Nashville 37207
(615) 769-4401 (Phone), (615) 769-4730 (Fax)
(615) 769-4401 (Phone), (615) 769-4730 (Fax)
Languages:
English
Kelly C Meyers, Nashville TN
Kelly C Meyers, Nashville TN
Specialties:
Nurse Practitioner
Address:
2020 21St Ave S, Nashville, TN 37212
Pyrvinium For The Treatment Of Cancer
Pyrvinium For The Treatment Of Cancer
US Patent:
2009009, Apr 16, 2009
Filed:
May 29, 2008
Appl. No.:
12/129250
Inventors:
Ethan Lee - Brentwood TN, US
Laura Lee - Brentwood TN, US
Curtis Thorne - Nashville TN, US
Emilios Tahinci - Nashville TN, US
Kelly Christian Meyers - Nashville TN, US
Laura Lee - Brentwood TN, US
Curtis Thorne - Nashville TN, US
Emilios Tahinci - Nashville TN, US
Kelly Christian Meyers - Nashville TN, US
International Classification:
A61K 38/02, G01N 33/48, C12Q 1/66, C12N 5/06, A61K 31/337
US Classification:
514 2, 436 63, 435 8, 435375, 514449
Abstract:
The present invention concerns a pyrvinium compound or an analog thereof for the treatment of cancers. This compound inhibits Wnt activity in the cells of cancers such as adrenocortical, hepatocellular, hepatoblastoma, malignant melanoma, ovarian, Wilm's tumor, Barrett's esophageal, glioma, bladder, breast, gastric, head & neck, lung cell, mesothelioma, and cervical cancers. The present invention also provides a method for assaying for compounds that alter Wnt pathway activity. Also provided are methods for treating Wnt-related non-cancer disease states.